WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of SINGULAIR. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with SINGULAIR use are currently not well understood [see Warnings and Precautions (5.1)].
Because of the risk of NP events, the benefits of SINGULAIR may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of SINGULAIR for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3)].
In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing SINGULAIR. Discuss the benefits and risks of SINGULAIR with patients and caregivers when prescribing SINGULAIR. Advise patients and/or caregivers to be alert for changes in behavior or new NP symptoms when taking SINGULAIR.
If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue SINGULAIR and contact a healthcare provider immediately [see Warnings and Precautions (5.1)]. WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS See full prescribing information for complete boxed warning.
Serious neuropsychiatric events have been reported in patients taking SINGULAIR (5.1). Discuss benefits and risks of SINGULAIR with patients and caregivers (5.1). Monitor for neuropsychiatric symptoms in patients taking SINGULAIR (5.1). Discontinue SINGULAIR immediately if neuropsychiatric symptoms occur (5.1). Because the benefits of SINGULAIR may not outweigh the potential risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies (1.3, 5.1).
Use: Labeled indications
- Prophylaxis and chronic treatment of asthma in patients 12 months of age and older
- .
Full indications and usage US FDA label
1 INDICATIONS AND USAGE SINGULAIR is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older (1.1). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older (1.2). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older.
Reserve use for patients who have an inadequate response or intolerance to alternative therapies (1.3). Limitations of Use: Not indicated to treat an acute asthma attack (5.2). 1.1 Asthma SINGULAIR ® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older. 1.3 Allergic Rhinitis SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older.
Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions (5.1)], reserve use for patients who have an inadequate response or intolerance to alternative therapies. 1.4 Limitations of Use SINGULAIR is not indicated for the treatment of an acute asthma attack.
Contraindications
4 CONTRAINDICATIONS SINGULAIR is contraindicated in patients with hypersensitivity to any of its components. Hypersensitivity to any component of SINGULAIR (4).
US FDA labelDosing: Adult
Administration (by indications): Asthma: Once daily in the evening for patients 12 months and older (2.1). Acute prevention of EIB: One tablet at least 2 hours before exercise for patients 6 years of age and older (2.2). Seasonal allergic rhinitis: Once daily for patients 2 years and older (2.3). Perennial allergic rhinitis: Once daily for patients 6 months and older (2.3).
Dosage (by age): 15 years and older: one 10-mg tablet (2). 6 to 14 years: one 5-mg chewable tablet (2). 2 to 5 years: one 4-mg chewable tablet or one packet of 4-mg oral granules (2). 6 to 23 months: one packet of 4-mg oral granules (2). Patients with both asthma and allergic rhinitis should take only one dose daily in the evening (2.4).
For oral granules: Must administer within 15 minutes after opening the packet (with or without mixing with food) (2.5).
2.1 Asthma
2.1 Asthma For asthma, administer SINGULAIR orally once daily in the evening, with or without food. There have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing. The following doses are recommended: Table 1: Recommended Dosage in Asthma Age Dose Adult and adolescent patients 15 years of age and older one 10 mg tablet Pediatric patients 6 to 14 years of age one 5 mg chewable tablet Pediatric patients 2 to 5 years of age one 4 mg chewable tablet or one packet of oral granules Pediatric patients 12 to 23 months of age Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. one packet 4 mg oral granules Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.
2.2 Exercise-Induced Bronchoconstriction (EIB)
2.2 Exercise-Induced Bronchoconstriction (EIB) For prevention of EIB, administer a single dose of SINGULAIR orally at least 2 hours, before exercise. The following doses are recommended: Table 2: Recommended Dosage in Exercise-Induced Bronchoconstriction (EIB) Age Dose Adult and adolescent patients 15 years of age and older one 10 mg tablet Pediatric patients 6 to 14 years of age Safety and effectiveness in patients younger than 6 years of age have not been established. one 5 mg chewable tablet An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.
Patients already taking SINGULAIR daily for another indication (including chronic asthma) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting β-agonist. Daily administration of SINGULAIR for the chronic treatment of asthma has not been established to prevent acute episodes of EIB.
2.3 Allergic Rhinitis
2.3 Allergic Rhinitis For allergic rhinitis, administer SINGULAIR orally once daily without regard to time of food ingestion. Time of administration in patients with allergic rhinitis can be individualized to suit patient needs. The following doses for the treatment of symptoms of seasonal allergic rhinitis are recommended: Table 3: Recommended Dosage in Seasonal Allergic Rhinitis Age Dose Adult and adolescent patients 15 years of age and older one 10 mg tablet Pediatric patients 6 to 14 years of age one 5 mg chewable tablet Pediatric patients 2 to 5 years of age Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established. one 4 mg chewable tablet or one packet of 4 mg oral granules The following doses for the treatment of symptoms of perennial allergic rhinitis are recommended: Table 4: Recommended Dosage in Perennial Allergic Rhinitis Age Dose Adult and adolescent patients 15 years of age and older one 10 mg tablet Pediatric patients 6 to 14 years of age one 5 mg chewable tablet Pediatric patients 2 to 5 years of age one 4 mg chewable tablet or one packet of 4 mg oral granules Pediatric patients 6 to 23 months of age Safety and effectiveness in pediatric patients younger than 6 months of age with perennial allergic rhinitis have not been established. one packet of 4 mg oral granules Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.
2.4 Asthma and Allergic Rhinitis
2.4 Asthma and Allergic Rhinitis For patients with both asthma and allergic rhinitis, administer only one SINGULAIR dose orally once daily in the evening. Patients who miss a dose should take the next dose at their regular time and should not take 2 doses at the same time.
2.5 Instructions for Administration of Oral Granules
2.5 Instructions for Administration of Oral Granules SINGULAIR 4-mg oral granules can be administered either directly in the mouth, dissolved in 1 teaspoonful (5 mL) of cold or room temperature baby formula or breast milk, or mixed with a spoonful of cold or room temperature soft foods; based on stability studies, only applesauce, carrots, rice, or ice cream should be used. The packet should not be opened until ready to use.
After opening the packet, the full dose (with or without mixing with baby formula, breast milk, or food) must be administered within 15 minutes. If mixed with baby formula, breast milk, or food, SINGULAIR oral granules must not be stored for future use. Discard any unused portion. SINGULAIR oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration.
However, liquids may be taken subsequent to administration. SINGULAIR oral granules can be administered without regard to the time of meals.
Dosing: Altered kidney function
8.7 Renal Impairment No dosage adjustment is recommended in patients with renal insufficiency [see Clinical Pharmacology (12.3)]. image of figure 1
Patients with Renal Impairment Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with renal insufficiency. No dosage adjustment is recommended in these patients. Male and Female Patients The pharmacokinetics of montelukast are similar in males and females.
Racial Groups Pharmacokinetic differences due to race have not been studied. Adolescents and Pediatric Patients Pharmacokinetic studies evaluated the systemic exposure of the 4-mg oral granule formulation in pediatric patients 6 to 23 months of age, the 4-mg chewable tablets in pediatric patients 2 to 5 years of age, the 5-mg chewable tablets in pediatric patients 6 to 14 years of age, and the 10-mg film-coated tablets in young adults and adolescents ≥15 years of age.
The plasma concentration profile of montelukast following administration of the 10-mg film-coated tablet is similar in adolescents ≥15 years of age and young adults. The 10-mg film-coated tablet is recommended for use in patients ≥15 years of age. The mean systemic exposure of the 4-mg chewable tablet in pediatric patients 2 to 5 years of age and the 5-mg chewable tablets in pediatric patients 6 to 14 years of age is similar to the mean systemic exposure of the 10-mg film-coated tablet in adults.
The 5-mg chewable tablet should be used in pediatric patients 6 to 14 years of age and the 4-mg chewable tablet should be used in pediatric patients 2 to 5 years of age. In children 6 to 11 months of age, the systemic exposure to montelukast and the variability of plasma montelukast concentrations were higher than those observed in adults.
Based on population analyses, the mean AUC (4296 ng•hr/mL [range 1200 to 7153]) was 60% higher and the mean C max (667 ng/mL [range 201 to 1058]) was 89% higher than those observed in adults (mean AUC 2689 ng•hr/mL [range 1521 to 4595]) and mean C max (353 ng/mL [range 180 to 548]). The systemic exposure in children 12 to 23 months of age was less variable, but was still higher than that observed in adults.
The mean AUC (3574 ng•hr/mL [range 2229 to 5408]) was 33% higher and the mean C max (562 ng/mL [range 296 to 814]) was 60% higher than those observed in adults. Safety and tolerability of montelukast in a single-dose pharmacokinetic study in 26 children 6 to 23 months of age were similar to that of patients two years and above [see Adverse Reactions (6.1)].
The 4-mg oral granule formulation should be used for pediatric patients 12 to 23 months of age for the treatment of asthma, or for pediatric patients 6 to 23 months of age for the treatment of perennial allergic rhinitis. Since the 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet, it can also be used as an alternative formulation to the 4-mg chewable tablet in pediatric patients 2 to 5 years of age.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No dosage adjustment is recommended in patients with mild-to-moderate hepatic insufficiency [see Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of SINGULAIR for asthma have been established in pediatric patients 6 to 14 years of age. Use of SINGULAIR for this indication is supported by evidence from well-controlled studies. Safety and efficacy data in this age group are similar to those seen in adults [see Adverse Reactions (6.1), Clinical Pharmacology, Specific Populations (12.3), and Clinical Studies (14.1, 14.2)].
The effectiveness of SINGULAIR for the treatment of seasonal allergic rhinitis in pediatric patients 2 to 14 years of age and for the treatment of perennial allergic rhinitis in pediatric patients 6 months to 14 years of age have been established and is supported by extrapolation from the demonstrated effectiveness in patients 15 years of age and older with allergic rhinitis as well as the assumption that the disease course, pathophysiology and the drug’s effect are substantially similar among these populations. The safety of SINGULAIR 4-mg chewable tablets in pediatric patients 2 to 5 years of age with asthma has been demonstrated by adequate and well-controlled data [see Adverse Reactions (6.1)].
Effectiveness of SINGULAIR in this age group is extrapolated from the demonstrated effectiveness in patients 6 years of age and older with asthma and is based on similar pharmacokinetic data, as well as the assumption that the disease course, pathophysiology and the drug’s effect are substantially similar among these populations. Effectiveness in this age group is supported by exploratory efficacy assessments from a large, well-controlled safety study conducted in patients 2 to 5 years of age.
The safety of SINGULAIR 4-mg oral granules in pediatric patients 12 to 23 months of age with asthma has been demonstrated in an analysis of 172 pediatric patients, 124 of whom were treated with SINGULAIR, in a 6-week, double-blind, placebo-controlled study [see Adverse Reactions (6.1)]. Effectiveness of SINGULAIR in this age group is extrapolated from the demonstrated effectiveness in patients 6 years of age and older with asthma based on similar mean systemic exposure (AUC), and that the disease course, pathophysiology and the drug's effect are substantially similar among these populations, supported by efficacy data from a safety trial in which efficacy was an exploratory assessment.
The safety of SINGULAIR 4-mg and 5-mg chewable tablets in pediatric patients aged 2 to 14 years with allergic rhinitis is supported by data from studies conducted in pediatric patients aged 2 to 14 years with asthma. A safety study in pediatric patients 2 to 14 years of age with seasonal allergic rhinitis demonstrated a similar safety profile [see Adverse Reactions (6.1)].
The safety of SINGULAIR 4-mg oral granules in pediatric patients as young as 6 months of age with perennial allergic rhinitis is supported by extrapolation from safety data obtained from studies conducted in pediatric patients 6 months to 23 months of age with asthma and from pharmacokinetic data comparing systemic exposures in patients 6 months to 23 months of age to systemic exposures in adults. The safety and effectiveness in pediatric patients below the age of 12 months with asthma, 6 months with perennial allergic rhinitis, and 6 years with exercise-induced bronchoconstriction have not been established.
Growth Rate in Pediatric Patients A 56-week, multi-center, double-blind, randomized, active- and placebo-controlled parallel group study was conducted to assess the effect of SINGULAIR on growth rate in 360 patients with mild asthma, aged 6 to 8 years. Treatment groups included SINGULAIR 5 mg once daily, placebo, and beclomethasone dipropionate administered as 168 mcg twice daily with a spacer device.
For each subject, a growth rate was defined as the slope of a linear regression line fit to the height measurements over 56 weeks. The primary comparison was the difference in growth rates between SINGULAIR and placebo groups. Growth rates, expressed as least-squares (LS) mean (95% CI) in cm/year, for the SINGULAIR, placebo, and beclomethasone treatment groups were 5.67 (5.46, 5.88), 5.64 (5.42, 5.86), and 4.86 (4.64, 5.08), respectively.
The differences in growth rates, expressed as least-squares (LS) mean (95% CI) in cm/year, for SINGULAIR minus placebo, beclomethasone minus placebo, and SINGULAIR minus beclomethasone treatment groups were 0.03 (-0.26, 0.31), -0.78 (-1.06, -0.49); and 0.81 (0.53, 1.09), respectively. Growth rate (expressed as mean change in height over time) for each treatment group is shown in FIGURE 1.
Figure 1: Change in Height (cm) from Randomization Visit by Scheduled Week (Treatment Group Mean ± Standard Error The standard errors of the treatment group means in change in height are too small to be visible on the plot of the Mean)
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects in clinical studies of montelukast, 3.5% were 65 years of age and over, and 0.4% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
The pharmacokinetic profile and the oral bioavailability of a single 10-mg oral dose of montelukast are similar in elderly and younger adults. The plasma half-life of montelukast is slightly longer in the elderly. No dosage adjustment in the elderly is required.
Administration
2.5 Instructions for Administration of Oral Granules SINGULAIR 4-mg oral granules can be administered either directly in the mouth, dissolved in 1 teaspoonful (5 mL) of cold or room temperature baby formula or breast milk, or mixed with a spoonful of cold or room temperature soft foods; based on stability studies, only applesauce, carrots, rice, or ice cream should be used. The packet should not be opened until ready to use. After opening the packet, the full dose (with or without mixing with baby formula, breast milk, or food) must be administered within 15 minutes. If mixed with baby formula, breast milk, or food, SINGULAIR oral granules must not be stored for future use. Discard any unused portion. SINGULAIR oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration. However, liquids may be taken subsequent to administration. SINGULAIR oral granules can be administered without regard to the time of meals.
US FDA labelDosage forms
Philippines
- Chewable tablet: 4 mg, 5 mg, 10 mg
- Film-coated tablet: 5 mg, 10 mg, 10 mg/5 mg
- Tablet: 4 mg, 5 mg, 10 mg
- Oral granule: 4 mg, 4 mg/sachet
- Granule: 4 mg
- Orodispersible tablet: 4 mg
- Pediatric granule: 4 mg
- Powder for suspension: 4 mg
Registered products in the Philippines
173 products registered with the Food and Drug Administration (FDA) Philippines list Montelukast as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products173
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AerokidsMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Glenmark Pharmaceuticals LimitedIndia | The Cathay YSS Distributors Co., Inc.Importer: Glenmark Philippines, Inc. | DRP-8043-03 | Sep 19, 2037 | |
AerokidsMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 14's (Box of 28's) | Rx | LEK S.A.Poland | The Cathay YSS Distributors Co., Inc.Importer: Sandoz Philippines Corporation | DRP-5345-01 | Apr 5, 2028 | |
AeromaxMontelukast (As Sodium) | 10 mg TabletAlu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | The Cathay Drug Co., Inc.Importer: Sandoz Philippines Corporation | DRP-3548-04 | Jul 15, 2027 | |
AirforzMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 5's (Box of 15's) | Rx | The ACME Laboratories Ltd.Bangladesh | TGP Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-6323-01 | Jul 12, 2028 | |
AirmaxxMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Bulacan | Trader: Euro-Health Care Exponents, Inc. | DRP-11510 | Mar 17, 2032 | |
AirmaxxMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-8221 | Aug 19, 2029 | |
AirmaxxMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY37122 | Dec 2, 2029 | |
AirmaxxMontelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY38133 | Jun 28, 2030 | |
AirokastMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: DB Manix International, Inc. | DR-XY36702 | Sep 25, 2029 | |
AirokastMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's (Box of 30's & 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: D.B. Manix International, Inc. | DRP-11501 | May 23, 2032 | |
AirokastMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu blister pack x 10’s Box of 100’s | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: DB Manix International, Inc. | DR-XY36700 | Sep 25, 2029 | |
ApiloneMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Pharmathen SAGreece | Saifen Drugs Philippines Inc. | DRP-15319 | Jun 18, 2029 | |
AurohexMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-4742 | Jan 20, 2032 | |
AurohexMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY40869 | Jul 24, 2027 | |
AurohexMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-17132 | Jul 24, 2027 | |
AurohexMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY41240 | Sep 11, 2027 | |
AurohexMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-17133 | Sep 11, 2027 | |
AverkazMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 5's Box of 15's | Rx | The ACME Laboratories Ltd.Bangladesh | Euro Generics International Phils., Inc. | DRP-6323 | Jul 12, 2028 | |
AverkazMontelukast (as sodium) | 4 mg Chewable TabletAlu-Alu blister pack x 10's (Box of 30's) | Rx | The ACME Laboratories Ltd.Bangladesh | Euro Generics International Phils., Inc. | DR-XY 46081 | Oct 9, 2027 | |
AverkazMontelukast (as Sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | The ACME Laboratories Ltd.Bangladesh | Euro Generics International Phils., Inc. | DRP-6324 | Feb 8, 2028 | |
AztmagrandMontelukast (as Sodium) | 5 mg Chewable TabletAluminum Strip Foil x 10’s (Box of 30’s) | Rx | Cadila Pharmaceuticals LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-3052-03 | Feb 3, 2030 | |
BrecareMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 7's (Box of 14's) | Rx | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3037 | Jun 26, 2032 | |
BronastMontelukast (as sodium) | 5 mg Chewable TabletAlu/PVC Blister Pack x 7's (Box of 14's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DR-XY38938 | Jan 11, 2031 | |
BronkastMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | CHMI Pharma, Inc. | DRP-6536-01 | Feb 14, 2027 | |
DialukastMontelukast (as Sodium) | 5 mg Chewable TabletAluminum Strip Foil x 10’s (Box of 30's) | Rx | Cadila Pharmaceuticals LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-3052-02 | Feb 3, 2030 | |
Efziekaz-10Montelukast (as sodium) | 10 mg Chewable TabletAluminum Foil Strip x 10's (Box of 30's and 100's} | Rx | Zim Laboratories Ltd.India | ADP Pharma CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881 | Apr 5, 2028 | |
EmakastMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 14's Box of 1 | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DR-XY45043 | Feb 10, 2031 | |
FuligetMontelukast (as Sodium) | 5 mg TabletAluminum Strip Foil x 4's (Box of 100's) | Rx | Diamond Laboratories Inc.Philippines | Full Health International Pharma | DRP-7607 | Jul 8, 2029 | |
Gentakast 10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and Box of 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-11451-02 | Mar 14, 2027 | |
Gentakast 5Montelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11452-01 | Mar 14, 2027 | |
Gentakast-4Montelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's, Box of 100's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11453-02 | Mar 14, 2027 | |
GeokastMontelukast (as Sodium) | 4 mg Powder for SuspensionAlu/PE/PET Foil Sachet x 1's (Box of 14's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DR-XY40537 | Jan 16, 2027 | |
Glemont-CT 4Montelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 2's as Physician's Sample (Box of 2's) | Rx | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines, Inc. | DRP-8043 | Nov 21, 2031 | |
Glemont-CT 5Montelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 2's as Physician's Sample (Box of 2's) | Rx | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines, Inc. | DRP-8042 | Nov 21, 2031 | |
Glemont-IR 10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Glenmark Generic Ltd.India | Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Ltd. | DR-XY42963 | Nov 15, 2028 | |
Glemont-IR 10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Glenmark Generic Ltd.India | Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Ltd. | DRP-17863 | Nov 15, 2028 | |
Gokast-10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11451-01 | Mar 14, 2027 | |
Gokast-4Montelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's and Box of 100's) | Rx | Ratnatris Pharmaceuticals Private LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11453-01 | Mar 14, 2027 | |
KastairMontelukast (as sodium) | 10 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 28's) | Rx | Amherst Laboratories, Inc.Philippines | Unilab, Inc. | DRP-2958 | Oct 24, 2030 | |
KastairMontelukast (As Sodium) | 10 mg TabletAlu/Alu Blister Pack x 14's (Box of 28's) Alu/Alu Blister Pack x 7's (Box of 28's) | Rx | Lek S.A.Poland | UNILAB, Inc.Importer: Sandoz Philippines Corporation | DRP-3548-03 | Jul 15, 2027 | |
KastairMontelukast (as Sodium) | 4 mg Oral GranulesPolyester/Alu/PE Foil Sachet x 4 mg (Box of 28's) | Rx | Bilim Ilac San. Ve Tic. A.Ş.Turkey | Unilab, Inc. | DRP-12270 | Jul 11, 2027 | |
Kastair EZ TabMontelukast (as sodium) | 5 mg TabletAluminum Foil Strip x 4's (Box of 28's) | Rx | Amherst Laboratories, Inc.Philippines | UNILAB, Inc. | DRP-2957-01 | Jul 6, 2027 | |
Kastair EZTabMontelukast | 4 mg TabletAluminum Foil Strip x 4's Box of 28's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY31298 | Aug 6, 2027 | |
KastelMontelukast (as sodium) | 10 mg Film-Coated TabletAlu-Alu Blister Pack of 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY38888 | Dec 23, 2030 | |
KastelMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Incorporated | DRP-11500 | Apr 18, 2027 | |
KastelMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Incorporated | DR-XY39416 | May 9, 2031 | |
KOTELKASTMontelukast (as sodium) | 10 mg TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-5279-05 | Apr 24, 2029 | |
LeukastMontelukast (As Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Hizon Laboratories, Inc.Philippines | GX International, Inc. | DRP-6741-03 | May 8, 2031 | |
LeukastMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY36106 | Jun 30, 2029 | |
LeukastMontelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY36105 | Jun 30, 2029 | |
LeukastMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Hizon Laboratories, IncPhilippines | GX International, Inc. | DRP-6840-03 | May 8, 2031 | |
LeukorexMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-6151 | May 14, 2030 | |
LeukorexMontelukast (as sodium) | 5 mg Chewable TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | New Myrex Laboratories Inc.Philippines | — | DRP-6150 | May 14, 2030 | |
LeuragenMontelukast (as Sodium) | 10 mg TabletAlu/ Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA GENERISCH TRADING INC. | DRP-5279-01 | Apr 24, 2029 | |
LucaztMontelukast (as sodium) | 10 mg TabletAlu/ Alu Blister Pack x 8's Box of 24's, 48's and 80's; Alu/ Alu Blister Pack x 10's Box of 30's, 50's and 100's | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-5279 | Apr 24, 2029 | |
Lukotrin 5Montelukast (as Sodium) | 5 mg Chewable TabletAluminum Strip Foil x 10’s (Box of 30’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3052-04 | Feb 3, 2030 | |
Mastic-5Montelukast (As Sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-6672 | Apr 29, 2031 | |
MauraMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRP-14612 | Oct 29, 2030 | |
Maura KidsMontelukast (as Sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 6 blister packs x 10 tablets; Box of 9 blister packs x 10 tablets) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY48385 | Sep 30, 2027 | |
Maura KidsMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 6 blister packs x 10 tablets; Box of 9 blister packs x 10 tablets) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRP-14472 | Sep 30, 2027 | |
Maura KidsMontelukast (As Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 6 blister packs x 10 tablets; Box of 9 blister packs x 10 tablets) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY48386 | Sep 30, 2027 | |
Maura KidsMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 6 blister packs packs x 10 tablets; Box of 9 blister packs x 10 tablets) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DRP-14613 | Sep 30, 2027 | |
Mediair-chewsMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 7's (Box of 14's) | Rx | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-3037-03 | Jun 26, 2032 | |
Mocast-10Montelukast (as Sodium) | 10 mg Chewable TabletAlu - Alu Blister Pack x 10's (Box of 100's) | Rx | Hiral Labs Ltd.India | Aglobal Care, Inc. | DRP-7992 | Aug 10, 2036 | |
Monagio-LMontelukast (as dihydrochloride as sodium) | 10 mg/5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Agio Pharmaceuticals Ltd.India | Agio Pharmaceuticals, Inc.Importer: Agio Pharmaceuticals Inc. | DR-XY49219 | Sep 20, 2029 | |
MonlastikMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals LtdIndia | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-4742-03 | Jan 20, 2027 | |
Monspire 4Montelukast (as Sodium) | 4 mg Chewable TabletStore at temperatures Alu/Alu Blister Pack x 10's (Box of 30's) | Rx | Aurobindo Pharma Limited (Unit VII)India | Medethix, Inc. | DRP-14142 | Jun 30, 2028 | |
MontairMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-11509 | Mar 17, 2027 | |
MontairMontelukast (as Sodium) | 4 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 30's); Alu-Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7134 | Apr 25, 2030 | |
MontairMontelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7135 | Dec 5, 2027 | |
Montas 10Montelukast (as sodium) | 10 mg Film Coated TabletAlu-Alu Blister Pack x 14's (Box of 28's) | Rx | INTAS PHARMACEUTICALS LIMITEDIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8472 | Nov 13, 2029 | |
Monte-H4Montelukast (as sodium) | 4 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-6894 | Jul 21, 2027 | |
Monte-H5Montelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box 100's) | Rx | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-6893 | Jul 21, 2027 | |
Montecad-5Montelukast (as Sodium) | 5 mg Chewable TabletAluminum Strip Foil x 10’s (Box of 30’s) | Rx | Cadila Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-3052 | Feb 3, 2030 | |
MontecareMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Bulacan | Trader: Interhealthcare Pharmaceuticals Inc. | DRP-11508 | Mar 17, 2037 | |
MonteclairMontelukast (as sodium) | 5 mg Chewable TabletFoil Strip x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-11125 | Feb 4, 2027 | |
MontefastMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma Inc. | DRP-11507 | Mar 17, 2027 | |
MontefendMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-11502 | May 23, 2027 | |
Monteglob-4Montelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14941 | Feb 22, 2029 | |
Monteglob-5Montelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14942 | Feb 22, 2029 | |
Montela 10Montelukast (As Sodium) | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DR-XY47817 | Mar 14, 2027 | |
Montela 5Montelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 20's) | Rx | Delta Pharma LimitedBangladesh | Biomed Pharma, Inc. | DR-XY44579 | Jun 18, 2028 | |
Montelair 10Montelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Hovid BERHADMalaysia | Hovid Inc. | DRP-6915 | Nov 14, 2029 | |
Montelair 5Montelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Hovid BerhadMalaysia | Hovid Inc. | DRP-6909 | Nov 17, 2029 | |
MontelastMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-4398 | Aug 19, 2029 | |
MontelastMontelukast (as Sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma, Inc. | DRP-3564 | Mar 17, 2031 | |
MontelifeMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack of 10’s (Box of 100's) | Rx | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading | DRP-19107 | Oct 28, 2031 | |
MontemaxMontelukast (as Sodium) | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 15's (Box of 15's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY32707 | Dec 12, 2031 | |
MontemaxMontelukast (as Sodium) | 4 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 30's); Alu-Alu Blister Pack x 15's (Box of 15's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY32840 | Jan 5, 2031 | |
MontemaxMontelukast (as Sodium) | 5mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 30's); Alu-Alu Blister Pack x 15's (Box of 15's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY32839 | Jan 5, 2030 | |
MonteproMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Malolos Bulacan | Trader: Metz Pharmaceuticals, Inc. | DRP-11505 | Apr 18, 2032 | |
MonteraphMontelukast (as sodium) | 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-5279-04 | Apr 24, 2029 | |
MonterespMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Gamot Philippines, Inc. | DRP-11499 | Apr 8, 2032 | |
MonterioMontelukast (as sodium) | 10 mg Film-Coated TabletsAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc | DRP-17005 | Sep 4, 2030 | |
Montesea-10Montelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Medchem International LimitedIndia | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-3403-02 | Nov 23, 2029 | |
MonteshieldMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-11504 | Apr 8, 2027 | |
MontesolvMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-11498 | Apr 8, 2027 | |
Montesur-10Montelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Medchem International LimitedIndia | Pharma-Surrey International, Inc. | DRP-3403 | Nov 23, 2029 | |
Montesur-5Montelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Medchem International LimitedIndia | Pharma-Surrey International, Inc. | DRP-3402 | Nov 23, 2029 | |
MonteventMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Euro-Health Care Exponents, Inc. | DRP-8221-01 | Aug 19, 2029 | |
MontezenMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research Inc. | DRP-11503 | Apr 8, 2027 | |
Montezyd 10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-10000 | Feb 27, 2032 | |
Montezyd 4Montelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10 (Box of 30's) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7566 | Jul 31, 2032 | |
Montezyd 5Montelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10 tablets (Box of 30's) | Rx | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7567 | Jul 31, 2032 | |
MontigetMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu-Alu Blister Pack x 7's (Box of 14's); Alu-Alu Blister Pack x 1's (Box of 1's) as Physician's Sample | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY40595 | Jul 18, 2030 | |
MontigetMontelukast (as Sodium) | 4 mg Chewable TabletAlu-Alu Blister Pack of 7's (Box of 14's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY32695 | Jul 18, 2030 | |
MontigetMontelukast (as sodium) | 4mg Pediatric GranulesAluminum Sachet Box of 14's Aluminum Sachet Box of 1's [Physician's Sample] | Rx | Getz Pharma (Pvt.) Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY34174 | Aug 29, 2030 | |
MontigetMontelukast (as Sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 7's (Box of 14's); Alu-Alu Blister Pack x 1's (Box of 1's) as Physician's Sample | Rx | Getz Pharma Pvt. Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY33009 | Jul 18, 2030 | |
MontilMontelukast (as sodium) | 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTION | DRP-5279-02 | Apr 24, 2029 | |
Montril-10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | DR-XY44285 | Jan 28, 2030 | |
Montril-10Montelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | DRP-17245 | Jan 28, 2030 | |
Montril-4Montelukast (as sodium) | 4 mg Orodispersible TabletAlu/Alu Blister Pack x 10 (Box of 30's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc | DR-XY44798 | Sep 3, 2030 | |
Montti-SMontelukast (as sodium) | 10 mg TabletAlu/ Alu Blister Pack x 8's (Box of 24's, 48's and 80's); Alu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-5279-07 | Apr 24, 2029 | |
MoscalairMontelukast (as Sodium) | 10 mg TabletAlu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-3548 | Jul 15, 2027 | |
MoscalairMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's);; Alu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-5342 | Apr 15, 2028 | |
MoscalairMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 20's);; Alu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-5345 | Apr 5, 2028 | |
NoneMontelukast | 10 mg Chewable TabletAluminum Foil Strip x 10's (Box of 30's) | Rx | Zim Laboratories Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881-04 | Apr 5, 2028 | |
NoneMontelukast (as sodium) | 10 mg Chewable TabletAluminum Foil Strip x 10's (Box of 30's) | Rx | Zim Laboratories Ltd.India | ATC Healthcare International Corp.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881-05 | Apr 5, 2028 | |
NoneMontelukast (as sodium) | 10 mg Chewable TabletAluminum Foil Strip x 10's (Box of 30's and 100's) | Rx | Zim Laboratories Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881-06 | Apr 5, 2028 | |
NoneMontelukast (as sodium) | 10 mg Chewable TabletAluminum Foil Strip x 10's Box of 30's and 100's | Rx | Zim Laboratories Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881-07 | Apr 5, 2028 | |
NoneMontelukast Sodium | 10 mg Film-coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | Popular Pharmaceuticals LtdBangladesh | Firmlink Pharma Phils. Co. | DR-XY42554 | Sep 6, 2028 | |
NoneMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample | Rx | Cadila Healthcare LimitedIndia | Metro Drug, Inc.Importer: Zydus Healthcare Philippines, Inc. | DRP-10000-01 | Feb 27, 2027 | |
NoneMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | Rx | Aristopharma Ltd.Bangladesh | Watsons Personal Care Stores (Philippines), Inc.Importer: Sahar International Trading, Inc. | DRP-17245-01 | Jan 28, 2030 | |
NoneMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health, Inc.Importer: Hexagon Pharmaceuticals | DRP-4742-04 | Jan 20, 2027 | |
NoneMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's | Rx | Hizon Laboratories, Inc.Philippines | — | DRP-6741 | Jul 15, 2030 | |
NoneMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Hizon Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-6741-02 | Feb 9, 2037 | |
NoneMontelukast Sodium | 4 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Popular Pharmaceuticals LtdBangladesh | Firmlink Pharma Phils. Co. | DR-XY42556 | Sep 6, 2028 | |
NoneMontelukast (as sodium) | 4 mg Chewable TabletAlu / Alu Blister Pack x 10's (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-17132-01 | Jul 24, 2027 | |
NoneMontelukast (as sodium) | 4 mg Chewable TabletAlu-Alu Blister Pack x 7's (Box of 14's) | Rx | The Searle Company LimitedPakistan | Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation | DRP-3783-01 | Jun 5, 2027 | |
NoneMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | Watsons Personal Care Stores (Philippines), Inc.Importer: Sandoz Philippines Corporation | DRP-5342-01 | Apr 15, 2028 | |
NoneMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10’s Box of 30’s and 100’s | Rx | Hizon Laboratories, Inc.Philippines | — | DRP-6839 | Jun 30, 2030 | |
NoneMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Glenmark Pharmaceuticals LimitedIndia | Ritemed Phils., Inc.Importer: Glenmark Philippines, Inc. | DRP-8043-01 | Nov 21, 2026 | |
NONEMontelukast (as sodium) | 4 mg GranulesAluminum Sachet (Box of 20's) | Rx | XL LABORATORIES PVT. LTD.India | PHARMAVITAL CORP.Importer: AMBICA INTERNATIONAL CORPORATION | DRP-4267-02 | Feb 26, 2028 | |
NoneMontelukast (as sodium) | 4 mg Oral GranulesAluminum/Paper Sachet x 4 mg (Box of 28's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY46496 | Jan 16, 2029 | |
NoneMontelukast Sodium | 5 mg Chewable TabletAlu/Alu blister pack x 10's Box of 30's | Rx | Popular Pharmaceuticals LtdBangladesh | Firmlink Pharma Phils. Co.Importer: Firmlink Pharma Phils. Co | DR-XY42552 | Sep 6, 2028 | |
NoneMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-17133-01 | Sep 11, 2027 | |
NoneMontelukast (as sodium) | 5 mg Chewable TabletAluminum Foil Strip x 10’s (Box of 30’s) | Rx | Zim Laboratories LimitedIndia | Actimed, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA chemicals & Pharmaceuticals Pvt. Ltd. | DRP-2920-01 | Apr 13, 2029 | |
NoneMontelukast (as sodium) | 5 mg Chewable tabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | The ACME Laboratories Ltd.Bangladesh | TGP Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-6324-01 | Feb 8, 2028 | |
NoneMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10’s Box of 100’s | Rx | Brawn Laboratories LimitedIndia | Reta DrugImporter: Ambica International Corporation | DRP-6672-02 | Oct 14, 2031 | |
NoneMontelukast (As Sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Brawn Laboratories LimitedIndia | PharmaVital Corp.Importer: Ambica International Corporation | DRP-6672-03 | Apr 29, 2031 | |
NoneMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | HIzon Laboratories, Inc.Philippines | — | DRP-6840 | Jun 30, 2030 | |
NoneMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10 tablets (Box of 30's); Alu-Alu Blister Pack x 10 tablets (Box of 10's as Physician's sample) | Rx | Cadila Healthcare LimitedIndia | Metro Drug Inc.Importer: Zydus Healthcare Philippines Inc. | DRP-7567-01 | Jul 31, 2027 | |
NoneMontelukast (as sodium) | 5 mg TabletAluminum Foil Strip x 4's Box of 28's | Rx | Amherst Laboratories, Inc.Philippines | RiteMED Phils., Inc. | DRP-2957 | Jul 6, 2027 | |
Novakast-10Montelukast (As Sodium) | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-11451 | Mar 14, 2027 | |
Novakast-4Montelukast (As Sodium) | 4mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-11453 | Mar 14, 2027 | |
Novakast-5Montelukast (As Sodium) | 5mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-11452 | Mar 14, 2027 | |
PediairMontelukast (as sodium) | 4 mg GranulesAluminum Sachet (Box of 20's) | Rx | XL Laboratories Pvt. Ltd.India | Medlink Pharma Phils. Inc.Importer: Ambica International Corporation | DRP-4267 | Feb 26, 2028 | |
PrimeairMontelukast | 10 mg Chewable TabletAluminum Foil Strip x 10's (Box of 30's and 100's) | Rx | Zim Laboratories Ltd.India | Primera Pharma CorporationImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881-01 | Apr 5, 2028 | |
PULMOCAZMontelukast (as sodium) | 5 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's) | Rx | Aurochem Pharmaceutical (I) Pvt. Ltd.India | Endure Medical, Inc. | DR-XY45358 | May 2, 2031 | |
SighwellMontelukast | 10 mg Chewable TabletAluminum Foil Strip x 10's (Box of 30's) | Rx | Zim Laboratories Ltd.India | Skymed Pharma DistributorImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-3881-02 | Apr 5, 2028 | |
SingulairMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack (Box of 28's) | Rx | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Organon (Philippines) Incorporated | DR-XY24157 | Sep 7, 2031 | |
SingulairMontelukast (as sodium) | 4 mg Chewable TabletAluminum Push-Through Blister x 7's (Box of 28's) | Rx | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Organon (Philippines) Incorporated | DRP-6234 | Mar 22, 2030 | |
SingulairMontelukast (as sodium) | 4 mg/sachet Oral GranulesPE/ AL/ LLDPE/ Aluminum Foil/ PET (28 sachets per box) | Rx | Patheon Manufacturing Services LLCUSA | Organon (Philippines) Incorporated | DRP-6235 | Aug 4, 2029 | |
SingulairMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister pack x 7's (Box of 28's) | Rx | Organon Pharma (UK) LimitedUnited Kingdom | Organon (Philippines) Incorporated | DRP-6233 | Sep 7, 2031 | |
SydenkastMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-6536 | Feb 14, 2027 | |
TekastMontelukast (as Sodium) | 10 mg Chewable TabletAlu/Alu Foil Strip x 10's (Box of 30's) | Rx | Zim Laboratories Ltd.India | Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-2750 | Feb 3, 2031 | |
TekastMontelukast (as sodium) | 5 mg Chewable TabletAluminum Foil Strip x 10’s (Box of 30’s) | Rx | Zim Laboratories LimitedIndia | Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-2920 | Apr 13, 2029 | |
TelkaztMontelukast (as sodium) | 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-5279-03 | Apr 24, 2029 | |
TerrakastMontelukast (as Sodium) | 10 mg Film-Coated TabletAlu/Alu Foil Strip x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DRP-12885 | Jul 4, 2031 | |
TerrakastMontelukast (as sodium) | 4 mg Chewable TabletAlu Strip Foil x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY45642 | Oct 25, 2028 | |
TerrakastMontelukast (as sodium) | 5 mg Chewable TabletAluminum Foil Strip x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY43233 | Feb 18, 2029 | |
UnbrandedMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-11506 | Mar 17, 2032 | |
UnbrandedMontelukast (as sodium) | 10 mg Film-Coated TabletAluminum Foil Strip x 4's Box of 28's | Rx | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: Unilab, Inc. | DRP-2958-02 | Oct 20, 2031 | |
UnbrandedMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 7's (Box of 14's) | Rx | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-3037-02 | Jun 26, 2032 | |
UnbrandedMontelukast (as Sodium) | 5 mg Chewable TabletAluminum Strip Foil x 10’s Box of 30’s | Rx | Cadila Pharmaceuticals LimitedIndia | ATC Healthcare International Corp.Importer: Ambica International Corporation | DRP-3052-05 | Feb 3, 2030 | |
UnbrandedMontelukast (as sodium) | 5 mg Chewable TabletAlu-Alu Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Ambicare Pharmaceuticals, Inc. | DRP-6672-01 | Oct 30, 2031 | |
VentekMontelukast (as sodium) | 4 mg Chewable TabletAlu/Alu Blister Pack x 7's (Box of 14's) | Rx | The Searle Company LimitedPakistan | Ambica International Corporation | DRP-3783 | Jun 5, 2027 | |
VentekMontelukast (as sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 7's (Box of 14's) | Rx | The Searle Company LimitedPakistan | Ambica International Corporation | DRP-3791 | Jun 6, 2027 | |
VitairMontelukast (as sodium) | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboraries, Inc.Philippines | Vitalink Health Products, Inc.Trader: Totalcare Pharma, Inc. | DRP-4398-01 | Aug 19, 2029 | |
VitairMontelukast (as Sodium) | 5 mg Chewable TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Vitalink Health Products, Inc.Trader: Totalcare Pharma, Inc. | DRP-3564-01 | Feb 3, 2032 | |
ZenkastMontelukast (as sodium) | 10 mg TabletAlu/ Alu Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Hale Medipoint Corp. | DRP-5279-06 | Apr 24, 2029 | |
(no brand name)Montelukast (As Sodium) | 10 mg TabletAlu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | Watsons Personal Care Stores (Philippines), Inc.Importer: Sandoz Philippines Corporation | DRP-3548-01 | Jul 15, 2027 | |
(no brand name)Montelukast (As Sodium) | 10 mg TabletAlu/Alu Blister Pack x 14's (Box of 28's) | Rx | Lek S.A.Poland | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-3548-02 | Jul 15, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets: 10 mg, beige, rounded square-shaped, film-coated tablets, with code MSD 117 on one side and SINGULAIR on the other. Chewable Tablets: 5 mg, pink, round, bi-convex-shaped, with code MSD 275 on one side and SINGULAIR on the other. Chewable Tablets: 4 mg, pink, oval, bi-convex-shaped, with code MSD 711 on one side and SINGULAIR on the other. Oral Granules: 4 mg, white granules with 500 mg net weight, packed in a child-resistant foil packet. Tablets: 10 mg (3) Chewable tablets: 5 mg and 4 mg (3) Oral granules: 4 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
Do not prescribe SINGULAIR to treat an acute asthma attack (5.2). Advise patients to have appropriate rescue medication available (5.2). Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute SINGULAIR for inhaled or oral corticosteroids (5.3). Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR (5.4).
Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral corticosteroid therapy (5.5 and 6.2). Inform patients with phenylketonuria that the 4-mg and 5-mg chewable tablets contain phenylalanine (5.6).
5.1 Neuropsychiatric Events
5.1 Neuropsychiatric Events Serious neuropsychiatric (NP) events have been reported with use of SINGULAIR. These postmarketing reports have been highly variable and included, but were not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thoughts and behavior (including suicide), tic, and tremor.
NP events have been reported in adult, adolescent, and pediatric patients with and without a previous history of psychiatric disorder. NP events have been reported mostly during SINGULAIR treatment, but some were reported after SINGULAIR discontinuation. Animal studies showed that montelukast distributes into the brain in rats [see Clinical Pharmacology (12.3)]; however, the mechanisms underlying SINGULAIR-associated NP events are currently not well understood.
Based upon the available data, it is difficult to identify risk factors for or quantify the risk of NP events with SINGULAIR use. Because of the risk of NP events, the benefits of SINGULAIR may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies.
Reserve use of SINGULAIR for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3)]. In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing SINGULAIR. Discuss the benefits and risks of SINGULAIR use with patients and caregivers when prescribing SINGULAIR.
Advise patients and/or caregivers to be alert for changes in behavior or for new NP symptoms when taking SINGULAIR. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue SINGULAIR and contact a healthcare provider immediately. In many cases, symptoms resolved after stopping SINGULAIR therapy; however, in some cases symptoms persisted after discontinuation of SINGULAIR.
Therefore, continue to monitor and provide supportive care until symptoms resolve. Re-evaluate the benefits and risks of restarting treatment with SINGULAIR if such events occur.
5.2 Acute Asthma
5.2 Acute Asthma SINGULAIR is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available. Therapy with SINGULAIR can be continued during acute exacerbations of asthma. Patients who have exacerbations of asthma after exercise should have available for rescue a short-acting inhaled β-agonist.
5.3 Concomitant Corticosteroid Use
5.3 Concomitant Corticosteroid Use While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids.
5.4 Aspirin Sensitivity
5.4 Aspirin Sensitivity Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR. Although SINGULAIR is effective in improving airway function in asthmatics with documented aspirin sensitivity, it has not been shown to truncate bronchoconstrictor response to aspirin and other non-steroidal anti-inflammatory drugs in aspirin-sensitive asthmatic patients [see Clinical Studies (14.1)].
5.5 Eosinophilic Conditions
5.5 Eosinophilic Conditions Patients with asthma on therapy with SINGULAIR may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events have been sometimes associated with the reduction of oral corticosteroid therapy.
Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between SINGULAIR and these underlying conditions has not been established [see Adverse Reactions (6.2)].
5.6 Risk in Patients with Phenylketonuria
5.6 Risk in Patients with Phenylketonuria SINGULAIR contains aspartame, a source of phenylalanine. Phenylalanine can be harmful to patients with phenylketonuria (PKU). Each 4 mg and 5 mg chewable tablet contains 0.674 mg and 0.842 mg of phenylalanine, respectively. Before prescribing SINGULAIR to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including SINGULAIR.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro studies using human liver microsomes indicate that CYP3A4, 2C8, and 2C9 are involved in the metabolism of montelukast.
Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of fexofenadine, did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the International Normalized Ratio (INR).
Effect of Montelukast on Cytochrome P450 (CYP) Enzymes Montelukast is a potent inhibitor of CYP2C8 in vitro.
However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) in 12 healthy individuals demonstrated that the pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating that montelukast does not inhibit CYP2C8 in vivo .
Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit CYP 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6.
Cytochrome P450 (CYP) Enzyme Inhibitors In vitro studies have shown that montelukast is a substrate of CYP 2C8, 2C9, and 3A4.
Co-administration of montelukast with itraconazole, a strong CYP 3A4 inhibitor, resulted in no significant increase in the systemic exposure of montelukast.
Data from a clinical drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) demonstrated that gemfibrozil, at a therapeutic dose, increased the systemic exposure of montelukast by 4.4-fold.
Adverse reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Neuropsychiatric Events [see Warnings and Precautions (5.1)] Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., Inc., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the following description of clinical trials experience, adverse reactions are listed regardless of causality assessment.
The most common adverse reactions (incidence ≥5% and greater than placebo; listed in descending order of frequency) in controlled clinical trials were: upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis. Adults and Adolescents 15 Years of Age and Older with Asthma SINGULAIR has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials.
In placebo-controlled clinical trials, the following adverse reactions reported with SINGULAIR occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo: Table 5: Adverse Reactions Occurring in ≥1% of Patients with an Incidence Greater than that in Patients Treated with Placebo SINGULAIR 10 mg/day (%) (n=1955) Placebo (%) (n=1180) Body As A Whole Pain, abdominal Asthenia/fatigue Fever Trauma 2.9 1.8 1.5 1.0 2.5 1.2 0.9 0.8 Digestive System Disorders Dyspepsia Pain, dental Gastroenteritis, infectious 2.1 1.7 1.5 1.1 1.0 0.5 Nervous System/Psychiatric Headache Dizziness 18.4 1.9 18.1 1.4 Respiratory System Disorders Influenza Cough Congestion, nasal 4.2 2.7 1.6 3.9 2.4 1.3 Skin/Skin Appendages Disorder Rash 1.6 1.2 Laboratory Adverse Reactions Number of patients tested (SINGULAIR and placebo, respectively): ALT and AST, 1935, 1170; pyuria, 1924, 1159. ALT increased AST increased Pyuria 2.1 1.6 1.0 2.0 1.2 0.9 The frequency of less common adverse reactions was comparable between SINGULAIR and placebo.
The safety profile of SINGULAIR, when administered as a single dose for prevention of EIB in adult and adolescent patients 15 years of age and older, was consistent with the safety profile previously described for SINGULAIR. Cumulatively, 569 patients were treated with SINGULAIR for at least 6 months, 480 for one year, and 49 for two years in clinical trials.
With prolonged treatment, the adverse reaction profile did not significantly change. Pediatric Patients 6 to 14 Years of Age with Asthma SINGULAIR has been evaluated for safety in 476 pediatric patients 6 to 14 years of age. Cumulatively, 289 pediatric patients were treated with SINGULAIR for at least 6 months, and 241 for one year or longer in clinical trials.
The safety profile of SINGULAIR in the 8-week, double-blind, pediatric efficacy trial was generally similar to the adult safety profile. In pediatric patients 6 to 14 years of age receiving SINGULAIR, the following reactions occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: pharyngitis, influenza, fever, sinusitis, nausea, diarrhea, dyspepsia, otitis, viral infection, and laryngitis.
The frequency of less common adverse reactions was comparable between SINGULAIR and placebo. With prolonged treatment, the adverse reaction profile did not significantly change. The safety profile of SINGULAIR, when administered as a single dose for prevention of EIB in pediatric patients 6 years of age and older, was consistent with the safety profile previously described for SINGULAIR.
In studies evaluating growth rate, the safety profile in these pediatric patients was consistent with the safety profile previously described for SINGULAIR. In a 56-week, double-blind study evaluating growth rate in pediatric patients 6 to 8 years of age receiving SINGULAIR, the following reactions not previously observed with the use of SINGULAIR in this age group occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: headache, rhinitis (infective), varicella, gastroenteritis, atopic dermatitis, acute bronchitis, tooth infection, skin infection, and myopia.
Pediatric Patients 2 to 5 Years of Age with Asthma SINGULAIR has been evaluated for safety in 573 pediatric patients 2 to 5 years of age in single- and multiple-dose studies. Cumulatively, 426 pediatric patients 2 to 5 years of age were treated with SINGULAIR for at least 3 months, 230 for 6 months or longer, and 63 patients for one year or longer in clinical trials.
In pediatric patients 2 to 5 years of age receiving SINGULAIR, the following reactions occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: fever, cough, abdominal pain, diarrhea, headache, rhinorrhea, sinusitis, otitis, influenza, rash, ear pain, gastroenteritis, eczema, urticaria, varicella, pneumonia, dermatitis, and conjunctivitis. Pediatric Patients 6 to 23 Months of Age with Asthma Safety and effectiveness in pediatric patients younger than 12 months of age with asthma have not been established.
SINGULAIR has been evaluated for safety in 175 pediatric patients 6 to 23 months of age. The safety profile of SINGULAIR in a 6-week, double-blind, placebo-controlled clinical study was generally similar to the safety profile in adults and pediatric patients 2 to 14 years of age. In pediatric patients 6 to 23 months of age receiving SINGULAIR, the following reactions occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo: upper respiratory infection, wheezing; otitis media; pharyngitis, tonsillitis, cough; and rhinitis.
The frequency of less common adverse reactions was comparable between SINGULAIR and placebo. Adults and Adolescents 15 Years of Age and Older with Seasonal Allergic Rhinitis SINGULAIR has been evaluated for safety in 2199 adult and adolescent patients 15 years of age and older in clinical trials. SINGULAIR administered once daily in the morning or in the evening had a safety profile similar to that of placebo.
In placebo-controlled clinical trials, the following reaction was reported with SINGULAIR with a frequency ≥1% and at an incidence greater than placebo: upper respiratory infection, 1.9% of patients receiving SINGULAIR vs. 1.5% of patients receiving placebo. In a 4-week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2-week studies.
The incidence of somnolence was similar to that of placebo in all studies. Pediatric Patients 2 to 14 Years of Age with Seasonal Allergic Rhinitis SINGULAIR has been evaluated in 280 pediatric patients 2 to 14 years of age in a 2-week, multicenter, double-blind, placebo-controlled, parallel-group safety study. SINGULAIR administered once daily in the evening had a safety profile similar to that of placebo.
In this study, the following reactions occurred with a frequency ≥2% and at an incidence greater than placebo: headache, otitis media, pharyngitis, and upper respiratory infection. Adults and Adolescents 15 Years of Age and Older with Perennial Allergic Rhinitis SINGULAIR has been evaluated for safety in 3357 adult and adolescent patients 15 years of age and older with perennial allergic rhinitis of whom 1632 received SINGULAIR in two, 6-week, clinical studies.
SINGULAIR administered once daily had a safety profile consistent with that observed in patients with seasonal allergic rhinitis and similar to that of placebo. In these two studies, the following reactions were reported with SINGULAIR with a frequency ≥1% and at an incidence greater than placebo: sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, and increased ALT.
The incidence of somnolence was similar to that of placebo. Pediatric Patients 6 Months to 14 Years of Age with Perennial Allergic Rhinitis The safety in patients 2 to 14 years of age with perennial allergic rhinitis is supported by the safety in patients 2 to 14 years of age with seasonal allergic rhinitis. The safety in patients 6 to 23 months of age is supported by data from pharmacokinetic and safety and efficacy studies in asthma in this pediatric population and from adult pharmacokinetic studies.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of SINGULAIR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders increased bleeding tendency, thrombocytopenia Immune system disorders hypersensitivity reactions including anaphylaxis, hepatic eosinophilic infiltration Psychiatric disorders including, but not limited to, agitation, aggressive behavior or hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, dysphemia (stuttering), hallucinations, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, suicidal thinking and behavior (including suicide), tic, and tremor [see Boxed Warning, Warnings and Precautions (5.1)] Nervous system disorders drowsiness, paraesthesia/hypoesthesia, seizures Cardiac disorders palpitations Respiratory, thoracic and mediastinal disorders epistaxis, pulmonary eosinophilia Gastrointestinal disorders diarrhea, dyspepsia, nausea, pancreatitis, vomiting Hepatobiliary disorders Cases of cholestatic hepatitis, hepatocellular liver-injury, and mixed-pattern liver injury have been reported in patients treated with SINGULAIR. Most of these occurred in combination with other confounding factors, such as use of other medications, or when SINGULAIR was administered to patients who had underlying potential for liver disease such as alcohol use or other forms of hepatitis.
Skin and subcutaneous tissue disorders angioedema, bruising, erythema multiforme, erythema nodosum, pruritus, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria Musculoskeletal and connective tissue disorders arthralgia, myalgia including muscle cramps Renal and urinary disorders enuresis in children General disorders and administration site conditions edema Patients with asthma on therapy with SINGULAIR may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These reactions have been sometimes associated with the reduction of oral corticosteroid therapy.
Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients [see Warnings and Precautions (5.5)].
Adverse reaction frequency tables (US label) US FDA label
| SINGULAIR 10 mg/day (%) (n=1955) | Placebo (%) (n=1180) | |
| Body As A Whole Pain, abdominal Asthenia/fatigue Fever Trauma | 2.9 1.8 1.5 1.0 | 2.5 1.2 0.9 0.8 |
| Digestive System Disorders Dyspepsia Pain, dental Gastroenteritis, infectious | 2.1 1.7 1.5 | 1.1 1.0 0.5 |
| Nervous System/Psychiatric Headache Dizziness | 18.4 1.9 | 18.1 1.4 |
| Respiratory System Disorders Influenza Cough Congestion, nasal | 4.2 2.7 1.6 | 3.9 2.4 1.3 |
| Skin/Skin Appendages Disorder Rash | 1.6 | 1.2 |
| Laboratory Adverse ReactionsNumber of patients tested (SINGULAIR and placebo, respectively): ALT and AST, 1935, 1170; pyuria, 1924, 1159. ALT increased AST increased Pyuria | 2.1 1.6 1.0 | 2.0 1.2 0.9 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not established a drug-associated risk of major birth defects [see Data]. In animal reproduction studies, no adverse developmental effects were observed with oral administration of montelukast to pregnant rats and rabbits during organogenesis at doses approximately 100 and 110 times, respectively, the maximum recommended human daily oral dose (MRHDOD) based on AUCs [see Data].
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly or moderately controlled asthma in pregnancy increases the maternal risk of perinatal adverse outcomes such as preeclampsia and infant prematurity, low birth weight, and small for gestational age. Data Human Data Published data from prospective and retrospective cohort studies have not identified an association with SINGULAIR use during pregnancy and major birth defects.
Available studies have methodologic limitations, including small sample size, in some cases retrospective data collection, and inconsistent comparator groups. Animal Data In embryo-fetal development studies, montelukast administered to pregnant rats and rabbits during organogenesis (gestation days 6 to 17 in rats and 6 to 18 in rabbits) did not cause any adverse developmental effects at maternal oral doses up to 400 and 300 mg/kg/day in rats and rabbits, respectively (approximately 100 and 110 times the AUC in humans at the MRHDOD, respectively).
Mechanism of action
12.1 Mechanism of Action The cysteinyl leukotrienes (LTC 4, LTD 4, LTE 4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT 1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells).
CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis.
Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT 1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD 4 at the CysLT 1 receptor without any agonist activity.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD 4 in asthmatics. Doses as low as 5 mg cause substantial blockage of LTD 4 -induced bronchoconstriction. In a placebo-controlled, crossover study (n=12), SINGULAIR inhibited early- and late-phase bronchoconstriction due to antigen challenge by 75% and 57%, respectively.
The effect of SINGULAIR on eosinophils in the peripheral blood was examined in clinical trials. In patients with asthma aged 2 years and older who received SINGULAIR, a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, compared with placebo, over the double-blind treatment periods. In patients with seasonal allergic rhinitis aged 15 years and older who received SINGULAIR, a mean increase of 0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% in placebo-treated patients, over the double-blind treatment periods; this reflects a mean difference of 12.3% in favor of SINGULAIR.
The relationship between these observations and the clinical benefits of montelukast noted in the clinical trials is not known [see Clinical Studies (14)].
Pharmacokinetics
Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.
In several studies, the mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults.
The elimination of montelukast was slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours).
Patients with Renal Impairment Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with renal insufficiency.
Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of fexofenadine, did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the International Normalized Ratio (INR).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Montelukast is rapidly absorbed following oral administration. After administration of the 10-mg film-coated tablet to fasted adults, the mean peak montelukast plasma concentration (C max) is achieved in 3 to 4 hours (T max). The mean oral bioavailability is 64%. The oral bioavailability and C max are not influenced by a standard meal in the morning.
For the 5-mg chewable tablet, the mean C max is achieved in 2 to 2.5 hours after administration to adults in the fasted state. The mean oral bioavailability is 73% in the fasted state versus 63% when administered with a standard meal in the morning. For the 4-mg chewable tablet, the mean C max is achieved 2 hours after administration in pediatric patients 2 to 5 years of age in the fasted state.
The 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet when administered to adults in the fasted state. The co-administration of the oral granule formulation with applesauce did not have a clinically significant effect on the pharmacokinetics of montelukast. A high fat meal in the morning did not affect the AUC of montelukast oral granules; however, the meal decreased C max by 35% and prolonged T max from 2.3 ± 1.0 hours to 6.4 ± 2.9 hours.
The safety and effectiveness of SINGULAIR in patients with asthma were demonstrated in clinical trials in which the 10-mg film-coated tablet and 5-mg chewable tablet formulations were administered in the evening without regard to the time of food ingestion. The safety of SINGULAIR in patients with asthma was also demonstrated in clinical trials in which the 4-mg chewable tablet and 4-mg oral granule formulations were administered in the evening without regard to the time of food ingestion.
The safety and effectiveness of SINGULAIR in patients with seasonal allergic rhinitis were demonstrated in clinical trials in which the 10-mg film-coated tablet was administered in the morning or evening without regard to the time of food ingestion. The comparative pharmacokinetics of montelukast when administered as two 5-mg chewable tablets versus one 10-mg film-coated tablet have not been evaluated.
Distribution Montelukast is more than 99% bound to plasma proteins. The steady state volume of distribution of montelukast averages 8 to 11 liters. Orally administered montelukast distributes into the brain in rats. Elimination The plasma clearance of montelukast averages 45 mL/min in healthy adults. Following an oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day fecal collections and <0.2% was recovered in urine.
Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile. In several studies, the mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults. The pharmacokinetics of montelukast are nearly linear for oral doses up to 50 mg.
During once-daily dosing with 10-mg montelukast, there is little accumulation of the parent drug in plasma (14%). Metabolism Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients. In vitro studies using human liver microsomes indicate that CYP3A4, 2C8, and 2C9 are involved in the metabolism of montelukast.
At clinically relevant concentrations, 2C8 appears to play a major role in the metabolism of montelukast. Specific Populations Patients with Hepatic Impairment Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast resulting in 41% (90% CI=7%, 85%) higher mean montelukast AUC following a single 10-mg dose.
The elimination of montelukast was slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours). No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. The pharmacokinetics of SINGULAIR in patients with more severe hepatic impairment or with hepatitis have not been evaluated.
Patients with Renal Impairment Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with renal insufficiency. No dosage adjustment is recommended in these patients. Male and Female Patients The pharmacokinetics of montelukast are similar in males and females.
Racial Groups Pharmacokinetic differences due to race have not been studied. Adolescents and Pediatric Patients Pharmacokinetic studies evaluated the systemic exposure of the 4-mg oral granule formulation in pediatric patients 6 to 23 months of age, the 4-mg chewable tablets in pediatric patients 2 to 5 years of age, the 5-mg chewable tablets in pediatric patients 6 to 14 years of age, and the 10-mg film-coated tablets in young adults and adolescents ≥15 years of age.
The plasma concentration profile of montelukast following administration of the 10-mg film-coated tablet is similar in adolescents ≥15 years of age and young adults. The 10-mg film-coated tablet is recommended for use in patients ≥15 years of age. The mean systemic exposure of the 4-mg chewable tablet in pediatric patients 2 to 5 years of age and the 5-mg chewable tablets in pediatric patients 6 to 14 years of age is similar to the mean systemic exposure of the 10-mg film-coated tablet in adults.
The 5-mg chewable tablet should be used in pediatric patients 6 to 14 years of age and the 4-mg chewable tablet should be used in pediatric patients 2 to 5 years of age. In children 6 to 11 months of age, the systemic exposure to montelukast and the variability of plasma montelukast concentrations were higher than those observed in adults.
Based on population analyses, the mean AUC (4296 ng•hr/mL [range 1200 to 7153]) was 60% higher and the mean C max (667 ng/mL [range 201 to 1058]) was 89% higher than those observed in adults (mean AUC 2689 ng•hr/mL [range 1521 to 4595]) and mean C max (353 ng/mL [range 180 to 548]). The systemic exposure in children 12 to 23 months of age was less variable, but was still higher than that observed in adults.
The mean AUC (3574 ng•hr/mL [range 2229 to 5408]) was 33% higher and the mean C max (562 ng/mL [range 296 to 814]) was 60% higher than those observed in adults. Safety and tolerability of montelukast in a single-dose pharmacokinetic study in 26 children 6 to 23 months of age were similar to that of patients two years and above [see Adverse Reactions (6.1)].
The 4-mg oral granule formulation should be used for pediatric patients 12 to 23 months of age for the treatment of asthma, or for pediatric patients 6 to 23 months of age for the treatment of perennial allergic rhinitis. Since the 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet, it can also be used as an alternative formulation to the 4-mg chewable tablet in pediatric patients 2 to 5 years of age.
Drug Interaction Studies Theophylline, Prednisone, and Prednisolone SINGULAIR has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, and prednisolone.
Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state, did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline [predominantly a cytochrome P450 (CYP) 1A2 substrate]. Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state, did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.
Oral Contraceptives, fexofenadine, Digoxin, and Warfarin In drug interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), digoxin, and warfarin. Montelukast at doses of ≥100 mg daily dosed to pharmacokinetic steady state did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.
Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of fexofenadine, did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP2C9, 3A4 and 1A2) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the International Normalized Ratio (INR). Thyroid Hormones, Sedative Hypnotics, Non-Steroidal Anti-Inflammatory Agents, Benzodiazepines, and Decongestants Although additional specific interaction studies were not performed, SINGULAIR was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions.
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. Cytochrome P450 (CYP) Enzyme Inducers Phenobarbital, which induces hepatic metabolism, decreased the area under the plasma concentration curve (AUC) of montelukast approximately 40% following a single 10-mg dose of montelukast.
No dosage adjustment for SINGULAIR is recommended. It is reasonable to employ appropriate clinical monitoring when potent CYP enzyme inducers, such as phenobarbital or rifampin, are co-administered with SINGULAIR. Effect of Montelukast on Cytochrome P450 (CYP) Enzymes Montelukast is a potent inhibitor of CYP2C8 in vitro.
However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) in 12 healthy individuals demonstrated that the pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating that montelukast does not inhibit CYP2C8 in vivo. Therefore, montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).
Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit CYP 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. Cytochrome P450 (CYP) Enzyme Inhibitors In vitro studies have shown that montelukast is a substrate of CYP 2C8, 2C9, and 3A4. Co-administration of montelukast with itraconazole, a strong CYP 3A4 inhibitor, resulted in no significant increase in the systemic exposure of montelukast.
Data from a clinical drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) demonstrated that gemfibrozil, at a therapeutic dose, increased the systemic exposure of montelukast by 4.4-fold. Co-administration of itraconazole, gemfibrozil, and montelukast did not further increase the systemic exposure of montelukast.
Based on available clinical experience, no dosage adjustment of montelukast is required upon co-administration with gemfibrozil [see Overdosage (10)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Montelukast 4 mg Chewable Tablet | ₱3.15–₱7.00Reference ₱4.99 | per tablet | DPRI procurement range |
| Montelukast 5 mg Chewable Tablet | ₱3.00–₱17.50Reference ₱5.00 | per tablet | DPRI procurement range |
| Montelukast 10 mg Tablet | ₱3.53–₱18.00Reference ₱7.25 | per tablet | DPRI procurement range |
| 4 mg (as sodium) chewable tablet | ₱20.50 | per tablet | PhilHealth GAMOT fixed fee |
| 4 mg (as sodium) granules in sachet | ₱22.00 | per sachet | PhilHealth GAMOT fixed fee |
| 5 mg (as sodium) chewable tablet | ₱15.50 | per tablet | PhilHealth GAMOT fixed fee |
| 10 mg (as sodium) tablet | ₱28.75 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Montelukast (as sodium salt) |
| PNF listing | Oral: 4 mg granules, sachetRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PNF listing | Oral: 4 mg and 5 mg chewable tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PNF listing | Oral: 10 mg tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. SINGULAIR · Organon LLC [US FDA-approved label, version 5, April 30, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482dcc92-b47f-4ea6-854a-f5ac2aea7842
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .